ApoB Monoclonal Antibody

This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels.

Introducing the AIF-M1 Monoclonal Antibody, a cutting-edge biotechnological innovation designed to revolutionize the field of immunology. This meticulously crafted antibody is meticulously engineered to specifically target and bind to the Apoptosis-Inducing Factor (AIF), a crucial protein involved in programmed cell death.

The AIF-M1 Monoclonal Antibody boasts an exceptional level of specificity and affinity, ensuring unparalleled accuracy in its binding to the AIF protein. This attribute enables researchers and clinicians to confidently utilize this antibody in a wide range of applications, including immunohistochemistry, immunofluorescence, and western blotting.

With its superior performance, the AIF-M1 Monoclonal Antibody offers an invaluable tool for investigating the intricate mechanisms underlying apoptosis and its implications in various physiological and pathological processes. Its exceptional sensitivity and reliability empower scientists to delve deeper into the intricate workings of cell death, shedding light on critical pathways and potential therapeutic targets.

Furthermore, the AIF-M1 Monoclonal Antibody is meticulously manufactured using state-of-the-art techniques, ensuring batch-to-batch consistency and reproducibility. Rigorous quality control measures are implemented throughout the production process, guaranteeing the utmost reliability and accuracy in experimental results.

In summary, the AIF-M1 Monoclonal Antibody represents a groundbreaking advancement in the realm of immunology, offering researchers and clinicians an indispensable tool for unraveling the complexities of apoptosis. With its exceptional specificity, sensitivity, and reliability, this antibody is poised to revolutionize the field, facilitating groundbreaking discoveries and paving the way for novel therapeutic interventions.